Revvity Alphalisa Surefire Ultra Human And Mouse Phospho-Tak1 (Thr184/187) Detection Kit, 50,000 Assay Points

Transforming growth factor β-activated kinase 1 (TAK1) is a member of the MAPK kinase kinase (MAPKKK) family and a key regulator of the innate immunity and the proinflammatory signaling pathways. TAK1 facilitates the activation of the nuclear factor B (NF-κB), c-Jun N-terminal kinase (JNK), and p38 pathways in response to the inflammatory proteins interleukin-1 (IL-1), tumor necrosis factor (TNF), and toll-like receptor (TLR) agonists. In addition, TAK1 mediates the signaling from T- and B-cell receptors, which is a crucial component of adaptive immunity. TAK1 is associated with various autoimmune diseases (rheumatoid arthritis, inflammatory bowel syndrome, kidney disease, skin inflammation, chronic pain) and cancers (mantle cell lymphoma, breast cancer, colon cancer).

The AlphaLISA SureFire Human and Mouse Phospho-TAK1 (Thr184/187) Detection Kit is a sandwich immunoassay for the quantitative detection of phospho-TAK1 (Thr184/187) in cellular lysates, using Alpha Technology.

Formats:

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

Alpha SureFire kits can be used for:

• Cellular kinase assays
• Receptor activation studies
• Screening

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).